New Haven, CT (Press Release) – Kleo Pharma­ceu­ticals, Inc. (Kleo), an immuno-oncology com­pany devel­op­ing next-generation syn­thet­ic bispecific com­pounds designed to emulate or en­hance the activity of biologics, announced today that CD38-ARM, a CD38 targeting anti­body recruiting molecule (ARM™) to treat multiple myeloma, will be its first prod­uct can­di­date to move into the clinic with antic­i­pated human studies to commence in 2020.

CD38-ARM is designed to recruit endogenous anti­bodies to multiple myeloma cancer cells, targeting them for destruction by natural killer (NK) cells and macrophages. CD38 is a val­i­dated multiple myeloma target, which is …